Lantus

Insulin glargine, the active ingredient in Lantus, is a long‑acting insulin analog presented as a 100 U/mL injectable solution for subcutaneous administration. It provides basal insulin coverage and is indicated for the management of type 1 and type 2 diabetes mellitus in adult and pediatric patients.

GNH USA supplies Lantus as a licensed, Good Distribution Practice‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing and logistics for this essential antidiabetic therapy and ensuring product integrity throughout the supply chain across multiple regions.

Lantus (insulin glargine) is used to provide basal insulin in the management of diabetes mellitus.

Type 1 diabetes mellitus: maintains basal insulin levels to control fasting glucose. Type 2 diabetes mellitus: provides steady basal insulin to improve glycemic control in patients requiring insulin therapy. Adjunct therapy in insulin‑treated patients: complements rapid‑acting insulin to achieve overall glycemic targets.

Lantus may cause a range of adverse reactions.

Common Side Effects: - Hypoglycemia, especially if meals are missed or dosing is excessive. - Injection‑site pain, redness, or swelling. - Weight gain due to improved glucose utilization. - Lipodystrophy at the injection site. - Mild allergic skin reactions. - Transient edema.

Serious or Rare Side Effects: - Severe hypoglycemia leading to loss of consciousness. - Anaphylactic reactions or severe urticaria. - Persistent severe injection‑site necrosis. - Acute bronchospasm. - Hypersensitivity with systemic symptoms. - Unexplained rapid weight loss.

When using Lantus, consider the following safety measures.

Hypoglycemia risk: monitor blood glucose regularly and adjust dose as needed. Renal or hepatic impairment: evaluate dose adjustments and monitor glucose trends. Pregnancy: Category B; use only if benefits outweigh potential risks. Elderly patients: initiate at lower doses and titrate cautiously. Drug interactions: review concomitant medications that may affect glucose levels. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Lantus can interact with several drug classes.

Major Interactions (Avoid): - Concurrent sulfonylureas or meglitinides: increased risk of severe hypoglycemia. - Beta‑blockers: may mask hypoglycemia symptoms. - Alcohol: potentiates hypoglycemic effect. - MAO inhibitors: unpredictable glucose fluctuations. - High‑dose corticosteroids: may require dose escalation.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: may raise blood glucose. - ACE inhibitors or ARBs: can enhance insulin sensitivity. - Oral contraceptives: may alter insulin requirements. - Lipid‑lowering agents (statins): monitor for rare hypersensitivity. - Antidepressants (SSRIs): observe for changes in glycemic control.